Announcement PDF Neurizon Therapeutics Limited Appendix 4E Preliminary final report 1. Company details Name of entity: Neurizon Therapeutics Limited ABN: 35 094 006 023 Reporting period: For the year ended 30 June 2026 Previous period: For the year ended 30 June 2025 2. Results for announcement to the market $ Other income up 844.2% to 17,769,524 Loss from ordinary activities after tax attributable to the owners of Neurizon Therapeutics Limited down 35.4% to (10,723,024) Loss for the year attributable to the owners of Neurizon Therapeutics Limited down 35.4% to (10,723,024) Dividends There were no dividends paid, recommended or declared during the current financial period. Operating Results The loss for the consolidated entity after providing for income tax amounted to $10,723,024 (30 June 2025: $16,593,619). Financial Position The net assets of the consolidated entity were $12,726,584 as at 30 June 2026 (30 June 2025: $2,820,571). 3. Net Tangible Asset 30 June 2026 30 June 2025 Cents Cents Net tangible assets per ordinary security 1.67 0.57 4. Control gained over entities Not applicable. 5. Loss of control over entities Not applicable. 6. Dividends Current period There were no dividends paid, recommended or declared during the current financial period. Previous period There were no dividends paid, recommended or declared during the previous financial period. 7. Details of associates and joint venture entities Not applicable. Neurizon Therapeutics Limited Appendix 4E Preliminary final report 8. Foreign entities Details of origin of accounting standards used in compiling the report: All foreign entities are in compliance with International Financial Reporting Standards which is equivalent to Australian Accounting Standards. 9. Audit qualification or review The 30 June 2026 financial statements and accompanying notes for Neurizon Therapeutics Limited have been audited and attached to the Appendix 4E. An unmodified opinion has been issued. 10. Attachments Details of attachments (if any): The Annual Report of Neurizon Therapeutics Limited for the year ended 30 June 2026 is attached. 11. Signed Signed ___________________________ Date: 25 August 2026 Mr. Sergio Duchini Interim Executive Chairman 2026 ANNUAL REPORT Hope on the Horizon Contents 02 Company Snapshot 04 Chairman’s Letter 06 Key Highlights 0 Financial report 89 Corporate directory Neurizon Therapeutics is a clinical-stage biotech company leading the development of treatments towards a promising new horizon for people living with neurodegenerative diseases. Our lead investigational therapy, NUZ-001, is being evaluated in the registrational Phase 2/3 HEALEY ALS Platform Trial for Amyotrophic Lateral Sclerosis (ALS), with topline results due in late Q2 CY2027. Our focus is resolute What’s on the horizon Science-led. Patient-driven. Globally connected. Neurizon Therapeutics Annual Report 2026 01 As a science-led, patient-driven and globally connected biotechnology company, we combine innovative research, disciplined clinical execution and strategic partnerships to translate scientific discoveries into meaningful outcomes for patients while creating long-term value for all stakeholders. Our goal is to develop disease-modifying therapies that address the biological mechanisms underlying neurodegeneration. Our lead investigational therapy NUZ-001, is being evaluated in the registrational Phase 2/3 HEALEY ALS Platform Trial for Amyotrophic Lateral Sclerosis (ALS). Following completion of enrolment of 250 participants into Phase 2/3 HEALEY ALS Platform Trial, Neurizon's immediate focus is on disciplined clinical execution as participants progress through treatment and follow-up, with topline results due in late Q2 CY2027. In parallel, the Company is advancing regulatory engagement, strengthening commercial readiness and continuing to expand the scientific understanding of NUZ-001. Beyond ALS, Neurizon is building the scientific foundation supporting the broader development of NUZ-001 across neurodegenerative diseases, including its potential to influence biological pathways involved in maintaining cellular protein homeostasis. Company Snapshot Lead Program: NUZ-001 Advancing a new frontier in neurodegenerative diseases At Neurizon Therapeutics, we are redefining how neurodegenerative diseases are treated – by addressing underlying biology, not just symptoms. Our goal is to transform the treatment of neurodegenerative diseases by developing disease-modifying therapies that address the biological pathways underlying neuronal degeneration. NUZ-001 is an orally available small molecule designed to support cellular protein homeostasis by enhancing multiple intracellular protein clearance pathways involved in the management of misfolded and aggregated proteins. Through its potential effects on autophagy and the ubiquitin-proteasome system, NUZ-001 is being investigated for its ability to support the maintenance of neuronal protein balance, a biological process disrupted across ALS and several other neurodegenerative diseases. NUZ-001 is currently being evaluated in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial as a potential treatment for ALS, the most common form of motor neurone disease (MND). Our Mechanism of Action Indication Amyotrophic Lateral Sclerosis (ALS) – the most common form of Motor Neurone Disease (MND) Mechanism of Action NUZ-001 addresses disrupted cellular protein homeostasis through activation of multiple protein clearance pathways (autophagy and proteasomal system) involved in managing misfolded and aggregated proteins. Trials Phase 2/3 HEALEY ALS Platform Trial Recruitment completed with 250 participants enrolled in less than 5 months Topline results due in late Q2 CY2027 Neurizon Therapeutics Annual Report 2026 02 FY2026 marked a defining year for Neurizon. The Company advanced NUZ-001 through late-stage clinical development while strengthening its scientific, regulatory, operational and financial foundations. These achievements reflect more than the successful delivery of individual milestones - they represent meaningful progress toward achieving our ambition to develop disease-modifying therapies that have the potential to make a meaningful difference for people living with neurodegenerative diseases. Our strategic priorities provide the framework for achieving that ambition and guide every decision we make for people living with ALS, partners and shareholders. The HEALEY ALS Platform Trial represents the major step in Neurizon's mission to develop a potential disease-modifying therapy for people living with ALS. As a global, adaptive registrational Phase 2/3 trial, it provides an efficient and rigorous pathway to evaluate NUZ-001 while generating the clinical evidence needed to support future regulatory and commercial opportunities. NUZ-001 is currently being evaluated as Regimen I of the HEALEY ALS Platform Trial. A clear strategic focus Our strategic priorities Delivering on our promise through advancing our clinical trial towards topline results: Neurizon Therapeutics Annual Report 2026 03 250 Participants 78 US Clinical Sites 3:1 Randomisation NUZ-001 : Placebo Topline Results Due Late Q2 CY2027 TRIAL INITIATION FEBRUARY 2026 TRIAL EXPANSION MAY 2026 ENROLMENT COMPLETED JULY 2026 TRIAL EXECUTION EARLY Q2 2027 DATABASE LOCK Q2 2027 TOPLINE RESULTS LATE Q2 2027 ADAPTIVE PLATFORM COLLABORATIVE PATIENT FOCUSED The HEALEY ALS Platform Trial – Regimen I – is a randomised, double-blind, placebo-con- trolled trial evaluating NUZ-001 in 250 participants with ALS across 78 leading clinical sites in the United States. Allows efficient evaluation and rapid advancement of promising therapies Led by Healey & NEALS with leading ALS experts, researchers and clinicians Designed to accelerate access to meaningful treatments for people living with ALS Accelerating Patient Hope and Access to Innovative ALS Treatment Driving Clinical Progress Unlocking the potential of Neurizon to address high unmet need in neurodegenerative diseases Delivering commercial readiness and stakeholder value Dear fellow shareholders, FY2026 was a defining year for Neurizon. Over the past twelve months, the Company transitioned into late-stage clinical development as NUZ-001 advanced into the registrational Phase 2/3 HEALEY ALS Platform Trial. Alongside this clinical progress, we strengthened the scientific, operational and financial foundations of the business, positioning Neurizon for its next phase of growth. At the centre of this progress remains our commitment to people living with ALS, the most common form of Motor Neurone Disease (MND). ALS is a devastating disease with an urgent need for more treatment options. That urgency continues to guide how we prioritise our activities and advance NUZ-001. One of our principal objectives for FY2026 was clear – advance NUZ-001 into the HEALEY ALS Platform Trial as quickly and efficiently as possible. Following constructive engagement with the US Food & Drug Administration (FDA), the Company secured clearance of its Investigational New Drug application, enabling NUZ-001 to enter the HEALEY ALS Platform Trial as Regimen I. These achievements represented the culmination of years of scientific, clinical and regulatory work and marked Neurizon's transition into late-stage clinical development. Our confidence in advancing NUZ-001 through late-stage clinical development was further strengthened by results from the 12-month Open-Label Extension study of NUZ-001 in people living with ALS. The study met its primary safety endpoint and provided encouraging preliminary signals of efficacy, including increased survival at the recommended Phase 2/3 dose compared to matched, untreated controls. Pleasingly, several participants continue to receive NUZ-001 to this day, through the TGA’s Special Access Scheme. With a regulatory pathway established, our focus shifted rapidly to clinical execution. First participant dosing commenced in February 2026 and recruitment exceeded expectations from the outset. Strong enrolment momentum provided an opportunity to expand Regimen I from 160 to 240 participants, strengthening the study. Importantly, through philanthropic support from HEALEY and disciplined cost management, this was achieved without increasing Neurizon’s expected funding requirements. Following year-end, enrolment of 250 participants was completed in less than five months from first participant dosing, making this the fastest enrolment achieved in the history of the HEALEY ALS Platform Trial. Beyond the significance of this milestone, it demonstrated the quality of execution across the program and accelerated the expected timing of topline efficacy and safety results to late Q2 CY2027. Clinical development is often defined by execution. Completing enrolment at this pace, while increasing the size of the study without increasing Neurizon's expected funding requirement, represents an outstanding achievement by everyone involved in the program. Our immediate priority is now the disciplined execution of the study through treatment completion, database lock and topline readout. While clinical execution remained our immediate priority, we also strengthened the long-term scientific foundation of NUZ-001. During the year, additional preclinical studies expanded our understanding of its mechanism of action, demonstrating activity across multiple intracellular protein clearance pathways, including autophagy and proteasomal activity, alongside restoration of BDNF, preservation of STMN2 expression and rebalancing of proteostasis. Together, these findings further support NUZ-001's potential as a disease-modifying therapy for ALS and reinforce its broader potential across neurodegenerative diseases characterised by impaired protein homeostasis. This scientific progress was complemented by the grant of an Australian patent extending protection through 2041. Interim Executive Chairman’s Le͵er Sergio Duchini Neurizon Therapeutics Annual Report 2026 04 While advancing the clinical program, we also strengthened the operational foundations required to support NUZ-001 through its next stage of development. A key priority has been establishing a reliable manufacturing and supply framework capable of supporting ongoing clinical development, regulatory activities and potential future commercialisation. Our relationship with Elanco Animal Health has been central to this strategy. During the year, we secured an exclusive global licensing agreement providing access to valuable manufacturing data and intellectual property, followed by a long-term strategic supply agreement for GMP monepantel, the active pharmaceutical ingredient in NUZ-001. Together, these agreements significantly strengthen our manufacturing capability, reduce supply chain risk and support the long-term development of the program. Funding late-stage clinical development has been another strategic priority. Throughout FY2026, the Board adopted a disciplined capital management approach, combining shareholder funding with government incentives and flexible financing solutions to maximise financial flexibility while minimising dilution. During the year, we strengthened our capital position through a combination of equity funding, non-dilutive government support and the establishment of a $20 million convertible note facility. We also secured eligibility under the Australian Government's R&D Tax Incentive program, including an Advance and Overseas Finding supporting eligible overseas expenditure associated with the HEALEY program. Following year-end, we further enhanced this strategy through a non-dilutive R&D financing facility with Dare Capital, enabling early access to anticipated R&D Tax Incentive refunds while reducing reliance on alternative funding sources. This reflects our continued focus on directing capital toward activities that advance or de-risk the clinical program while protecting long-term shareholder value. As Neurizon entered this next phase of development, our governance evolved accordingly. During the year, I assumed the role of Interim Executive Chair and we welcomed Dr Ross Murdoch as Non-Executive Director. Ross brings extensive global pharmaceutical and biotechnology experience spanning neurodegenerative diseases, clinical development and commercial strategy. I would also like to acknowledge the valuable contribution of Dr Michael Thurn, who retired from the Board during the year. As we enter FY2027, our priorities are clear. With enrolment complete, our immediate focus is the disciplined execution of Regimen I as participants progress through treatment and follow-up phase ahead of anticipated topline efficacy and safety results in late Q2 CY2027. Alongside the clinical program, we will continue advancing regulatory engagement, strengthening the scientific evidence supporting NUZ-001, maintaining manufacturing readiness, progressing strategic partnering activities and building the organisational capability required for the Company's next phase of development, including the appointment of a new Chief Executive Officer. Our focus is not only on reaching the next clinical milestone, but on ensuring Neurizon is well positioned to realise the opportunities that may follow. As we pursue these priorities, we remain mindful of the people at the heart of our mission. I would like to sincerely thank every participant and family who has chosen to take part in Regimen I, together with the investigators, research coordinators, clinical site teams and the Sean M. Healey & AMG Center for ALS. Their commitment has enabled the study to progress at an exceptional pace and continues to advance the development of potential new treatment options for this devastating disease. I would also like to thank my fellow Directors, our employees, advisers and our scientific, clinical and commercial collaborators for their dedication throughout an exceptionally important year for Neurizon. Finally, to our shareholders, thank you for your continued confidence in Neurizon and our strategy. FY2026 was a defining year in the Company's evolution. We transitioned into late-stage clinical development, strengthened the scientific, operational and financial foundations of the business, and established a clear path towards one of the most significant milestones in our history. While clinical development is never without risk, we enter FY2027 as a stronger and more mature organisation with a disciplined strategy, a substantially advanced clinical program and an unwavering commitment to improving the lives of people living with ALS. I look forward to updating you as we continue this important journey together. Yours sincerely, Sergio Duchini Interim Executive Chairman Neurizon Therapeutics Limited Neurizon Therapeutics Annual Report 2026 05 First Participant Dosed in HEALEY ALS Trial Executing a Registrational Clinical Program Strengthening the Scientific Foundation of NUZ-001 Strengthening Capital and Growth Foundations Building Commercial Readiness HEALEY ALS Trial Expanded Regimen I Fully Enrolled Key Highlights FY2026 was a transformational year for Neurizon. The Company successfully completed enrolment in the registrational Phase 2/3 HEALEY ALS Platform Trial, strengthened its capital position, advanced manufacturing and regulatory readiness, and continued to build the scientific foundation supporting NUZ-001. Together, these achievements reinforce the strength of Neurizon's science and position the Company to pursue significant clinical, scientific and commercial opportunities in the years ahead. Completed enrolment of 250 participants across 78 U.S. sites in less than five months, becoming the fastest enrolment in HEALEY ALS Platform Trial and accelerating anticipated topline results to late Q2 CY2027. First participant dosed in Regimen I of the registrational Phase 2/3 HEALEY ALS Platform Trial, marking the commencement of late-stage clinical development. Long-Term Supply Agreement with Elanco Secured long-term manufacturing and supply agreement securing access to GMP monepantel for continued clinical development and potential future commercialisation of NUZ-001. Intellectual Property Strengthened Secured NEURIZON® trademark protection across priority global markets and Australian patent protection for NUZ-001 through 2041. Protein Homeostasis Mechanism Expanded Demonstrated activity across multiple intracellular protein clearance pathways, further supporting its differentiated mechanism addressing disrupted protein homeostasis. Multi-Pathway Clearance Activity Demonstrated Generated evidence of activity across autophagy and the ubiquitin-proteasome system, supporting the management of misfolded and aggregated proteins. Platform Potential Reinforced Generated additional scientific evidence supporting the broader potential of NUZ-001 across neurodegenerative diseases. Strengthened Capital Position Raised approximately $20.8 million through equity raises, supporting continued execution through key clinical milestones. Access to Non-Dilutive Funding Strengthened non-dilutive funding position by securing the Australian Government's R&D Tax Incentive and establishing an R&D financing facility providing early access to the FY2026 incentive. Expanded the participant cohort from 160 to 250, while maintaining the original statistical power and funding through topline results. Neurizon Therapeutics Annual Report 2026 06 2026 ANNUAL REPORT Financial Report 10 8 9 40  2 3 78 80 81 89 86 Contents Directors' report Auditor's independence declaration Consolidated Statement of profit or loss and other comprehensive income Consolidated Statement of financial position Consolidated Statement of changes in equity Consolidated Statement of cash flows Notes to the financial statements Consolidated entity disclosure statement Directors' declaration Independent auditor's report to the members of Neurizon Therapeutics Limited Shareholder information Corporate directory Directors’ Report 01 For the year ended 30 June 2026 Annual Report 2026 Neurizon Therapeutics Limited Directors' report 30 June 2026 The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity' or 'Group') consisting of Neurizon Therapeutics Limited (referred to hereafter as the 'Company' or 'parent entity' or 'Neurizon') and the entities it controlled at the end of, or during, the year ended 30 June 2026. Directors The following persons were directors of Neurizon Therapeutics Limited during the whole of the financial year and up to the date of this report, unless otherwise stated: Mr. Sergio Duchini Interim Executive Chairman (transitioned from Non- Executive Chairman on 16 March 2026) Mr. Marcus Hughes Non-Executive Director Dr. Katie MacFarlane Non-Executive Director Dr. Ross Murdoch Non-Executive Director (appointed on 8 May 2026) Dr. Michael Thurn Managing Director and Chief Executive Officer (resigned on 16 March 2026); Non-Executive Director (retired on 8 May 2026) Principal activities The principal continuing activities constituted by Neurizon Therapeutics Limited and the entities it controlled during the year were to develop its own intellectual property for the treatment of neurological diseases. Dividends There were no dividends paid, recommended or declared during the current or previous financial year. Review of operations The loss for the consolidated entity after providing for income tax amounted to $10,723,024 (30 June 2025: $16,593,619). Neurizon Therapeutics Limited (“Neurizon” or “the Company”), is a late clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neurone Disease (MND). During FY2026, Neurizon delivered transformational progress through a series of regulatory, clinical, manufacturing, intellectual property, corporate and funding milestones, culminating in NUZ-001’s entry into the pivotal Phase 2/3 HEALEY ALS Platform Trial. These achievements were delivered alongside continued execution against the Company’s four strategic pillars – advancing patient access to innovative ALS/MND treatments, driving clinical progress, unlocking the potential of NUZ-001 to treat the range of neurodegenerative diseases and delivering commercial readiness and stakeholder value. Neurizon Therapeutics Annual Report 2026 10 Neurizon Therapeutics Limited Directors' report 30 June 2026 Clinical, Regulatory Progress and Preclinical Scientific Development Neurizon’s clinical and regulatory pathway was defined by the resolution of the FDA’s clinical hold on the NUZ- 001 Investigational New Drug (IND) application and the Company’s subsequent entry into the HEALEY ALS Platform Trial. In late July 2025, the Company submitted a comprehensive Clinical Hold Complete Response (CHCR) to the US Food & Drug Administration (FDA), incorporating new data from two 28-day bridging pharmacokinetic studies in rats and dogs requested by the regulator to assess the adequacy of systemic exposure to NUZ-001. While the FDA’s review was delayed in August 2025 due to agency-wide resourcing constraints, the Company received positive written guidance confirming its proposed strategy was appropriate, and in early October 2025 the FDA formally accepted the CHCR and lifted the clinical hold on the NUZ-001 IND. This represented a defining regulatory milestone for the Company, clearing the path for NUZ-001’s entry into the HEALEY ALS Platform Trial and providing a strong regulatory foundation to unlock the molecule’s platform potential across other neurodegenerative diseases. In August 2025, Neurizon reported positive topline results from the Open-Label Extension (OLE) study of NUZ- 001, which met its primary endpoint, confirming that long-term treatment was safe and well-tolerated. Based on a study population of 12 participants, preliminary efficacy analysis against matched historical controls from the PRO-ACT database showed a significant survival benefit (76.7% reduction in risk of death, HR=0.233, p=0.0013), an estimated median survival extension of approximately 16 months, and a slowing of functional and respiratory decline of 31% (p=0.145) and 43% (p=0.078) respectively. While the small sample size warrants caution in interpreting these preliminary findings, the results reinforced the rationale for advancing NUZ-001 into the pivotal HEALEY ALS Platform Trial. In December 2025, following completion of the FDA’s 30-day review of the associated protocol amendment, NUZ-001 was formally cleared for inclusion in the HEALEY ALS Platform Trial and confirmed as Regimen I – representing official entry into the world’s leading adaptive Phase 2/3 ALS clinical development platform. The HEALEY ALS Platform Trial, conducted by the Sean M. Healey & AMG Center for ALS at Mass General Brigham in partnership with the Network for Excellence in ALS (NEALS), is a multicentre, double-blind, placebo-controlled study evaluating multiple investigational ALS therapies concurrently under a shared master protocol across 78 clinical sites in the United States. Following Institutional Review Board (IRB) approvals and clinical site activations, first participant dosing in Regimen I was achieved in February 2026. In May 2026, Regimen I was expanded from 160 to 240 participants to maintain the trial’s original statistical power, in the absence of a concurrent regimen. Importantly, the expansion was achieved with no change to Neurizon’s funding requirement through to topline readout, in part as a result of philanthropic funding from the Sean M. Healey & AMG Center for ALS. Subsequent to year end, on 17 July 2026, the Company advised that Regimen I had completed enrolment in under five months from first participant dosing, with a total of 250 participants. This marked the fastest site activation and enrolment of any regimen in HEALEY’s history, with topline efficacy and safety results now anticipated in late Q2 CY2027. Neurizon Therapeutics Annual Report 2026 11 Neurizon Therapeutics Limited Directors' report 30 June 2026 Alongside strong clinical progress, Neurizon continued to build the scientific evidence base for NUZ-001 as a potential platform therapy for other neurodegenerative diseases and to better understand the mechanism of action. In October 2025, the Company presented preclinical and trial-methodology research at the NEALS Annual Meeting, highlighting NUZ-001’s brain penetration and reduction of TDP-43 aggregation. In March 2026, new preclinical data presented at the American Society for Experimental NeuroTherapeutics (ASENT) Annual Meeting demonstrated NUZ-001’s activity in Huntington’s disease models, including restoration of Brain-Derived Neurotrophic Factor (BDNF) levels, reduced apoptosis and enhanced autophagic markers in human neuronal systems. This was followed by delivery of additional data showing NUZ-001 activated the ubiquitin proteasome pathway – a complementary protein clearance mechanism to autophagy – reinforcing the Company’s hypothesis of a differentiated, multi-pathway approach to restoring protein homeostasis in neurodegenerative disease. In June 2026, at the BIO International Convention, Neurizon presented additional mechanism-of-action data demonstrating preservation of STMN2 expression in motor neurons and rebalancing of proteostasis across neuronal models, further differentiating NUZ-001’s mechanism of action. Manufacturing Process Neurizon made significant progress in de-risking NUZ-001’s manufacturing and supply pathway during the period. Having procured 100 kilograms of GMP-manufactured NUZ-001 and launched a manufacturing campaign with Catalent in the prior year, the Company completed production of three GMP registration batches of NUZ-001 tablets during the December 2025 quarter, using full-scale commercial processes compliant with FDA and ICH requirements. Produced at a one-tenth commercial scale, these batches will underpin long-term stability studies, shelf-life determination and the Chemistry, Manufacturing and Controls (CMC) module of Neurizon’s planned New Drug Application (NDA) with the FDA. This manufacturing progress was supported by Neurizon’s global licensing agreement with Elanco Animal Health (Elanco), executed on 1 July 2025, which provided the Company with exclusive access to the group’s comprehensive package of non-clinical animal safety and GMP manufacturing data for monepantel, the active pharmaceutical ingredient in NUZ-001. Building on this agreement, in November 2025, Elanco's appointment of Ms Justine Conway (previously Elanco’s Head of Business Development) as a Board Observer to Neurizon and in December 2025 Elanco participated in an equity placement undertaken by Neurizon, becoming one of the Company’s top five shareholders. Further, in June 2026, Neurizon executed a long-term, strategic supply agreement with Elanco, securing GMP-compliant supply of human health specification GMP monepantel over an initial five-year term. The license agreement and long-term supply agreement, materially reduce Neurizon’s manufacturing and supply-chain risk and strengthen the Company’s commercial and regulatory readiness. Strengthened Intellectual Property (IP) Portfolio Neurizon further strengthened its global IP position during the period. In October 2025, the Company was granted an Australian patent covering NUZ-001 for the treatment of neurodegenerative diseases, including ALS/MND, Alzheimer’s disease, Huntington’s disease and Parkinson’s disease, providing protection through to May 2041 and complementing the expedited US method of use patent granted in the prior year. Neurizon also completed registered trademark protection for the NEURIZON® brand across all priority global commercial markets, including t